NL-OMON32316
已完成
4 期
Top Institute Pharma (TIP) - research UMCU-rheumatology: *Metabolic adverse events/co-morbidity in chronic rheumatoid arthritis patients* - Top Institute Pharma (TIP) - research UMCU-rheumatology
niversitair Medisch Centrum Utrecht0 个研究点目标入组 300 人待定
概览
- 阶段
- 4 期
- 干预措施
- 未指定
- 疾病 / 适应症
- diabetes
- 发起方
- niversitair Medisch Centrum Utrecht
- 入组人数
- 300
- 状态
- 已完成
- 最后更新
- 去年
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •Diagnosis reumatoïd arthritis with disease duration \> 2 years.
排除标准
- 未提供
结局指标
主要结局
未指定
相似试验
已完成
不适用
Pharmacy pilot to detect hypertension and atrial fibrillatioHypertension and atrial fibrillationCirculatory SystemISRCTN26825087Irish Pharmacy Union1,000
尚未招募
不适用
To study theeEffect of an Ayurvedic Drug Trimurthy Ras for treatment of Medoroga (Dyslipidaemia - Blood fat levels)Health Condition 1: E782- Mixed hyperlipidemiaCTRI/2019/03/018228Dr Ratna Priya Darsini Y
尚未招募
2 期
Effect of Brahmighrta in the management of DementiaHealth Condition 1: F192- Other psychoactive substance dependenceCTRI/2022/11/047302Banaras Hindu University
进行中（未招募）
不适用
Estudio farmacogenético exploratorio, multinacional, multicéntrico y con una sola toma de muestras de sangre del ensayo REGARD (REbif vs Glatiramer Acetate in Relapsing MS Disease). A multinational, multicenter, single blood sampling exploratory pharmacogenetic study of the REGARD (the REbif vs Glatiramer Acetate in Relapsing MS Disease) trial - REGARD-PGxEsclerosis MúltipleMedDRA version: 12.0Level: PTClassification code 10028245Term: Multiple sclerosisEUCTR2009-016087-37-ESMerck Serono S.A. - Geneva325
暂停
1 期
A Clinical Pharmacology Trial of Brexpiprazole Long Acting Injectable (LAI) Administered as a Single Dose in Patients With SchizophreniaSchizophreniaJPRN-jRCT2061210051Matsumaru Takehisa60